Key Highlights

  • Beta Bionics (NASDAQ:BBNX) reports against a consensus loss of USD 0.51 per share after second-quarter sales rose 38% to USD 32.0 million, with full-year net sales guidance of USD 131 million to USD 136 million unchanged.
  • OrthoPediatrics (NASDAQ:KIDS) is expected to post a loss of USD 0.21 per share, against USD 0.30 in the second quarter, after raising 2026 revenue guidance to USD 265.0 million to USD 269.0 million.
  • Pulmonx (NASDAQ:LUNG) reports against a consensus loss of USD 0.26 per share, after second-quarter revenue of USD 22.8 million, a narrower loss and a share gain of about 14.4%.
  • All three report after the close on Tuesday, October 27, 2026, and the Federal Reserve decides on Wednesday, October 28, 2026, which matters for loss-making device companies that depend on funding.

Beta Bionics (NASDAQ:BBNX): pharmacy growth and rising costs

Beta Bionics (NASDAQ:BBNX) sells the iLet bionic pancreas, an insulin delivery system that adjusts doses automatically for people with type 1 diabetes, and it reports third-quarter results after the close on Tuesday, October 27, 2026. Consensus calls for a loss of USD 0.51 per share. In the second quarter, reported on Thursday, July 30, 2026, net sales were USD 32.0 million, with the pharmacy channel up 153% to USD 11.6 million and the durable medical equipment channel up 9% to USD 20.4 million. The net loss was USD 23.4 million, or USD 0.53 per share. Results cannot be known in advance.

The company is shifting from durable medical equipment suppliers to the pharmacy channel, which lets patients obtain the pump through a standard prescription route and can speed adoption. Management expects the pharmacy channel to account for 37% to 39% of new patient starts. Growth is being bought at a cost, since second-quarter operating expenses rose about 37% to USD 44.5 million, with sales and marketing up 58% to USD 24.6 million. Cash and investments of USD 225.2 million at June 30, 2026 provide funding. The pipeline adds further reasons to watch: enrolment began in July for a pivotal trial in type 2 diabetes, with a label expansion expected around mid-2027, and the patch pump is expected to be fully commercial by the end of the second quarter of 2027, subject to clearance from the Food and Drug Administration.

The bull case is sales near the upper half of the USD 131 million to USD 136 million range, a pharmacy share at or above 39% and a loss narrower than USD 0.51, which would likely lift the shares. The bear case is gross margin below the 58.5% to 59.5% range or faster cash burn, which would likely pressure a growth stock valued on future sales.

OrthoPediatrics (NASDAQ:KIDS): a scoliosis test of the inflection claim

OrthoPediatrics (NASDAQ:KIDS) is a medical device company focused on children's orthopaedic conditions, and it reports after the close on Tuesday, October 27, 2026. Consensus estimates call for a loss of USD 0.21 per share. In the second quarter, revenue rose 15% to USD 70.5 million, gross margin was 74% and the loss was USD 0.30 per share. The company then raised 2026 revenue guidance from USD 263.0 million to USD 267.0 million to a new range of USD 265.0 million to USD 269.0 million, implying 12% to 14% growth, and reiterated adjusted EBITDA of about USD 25.0 million and breakeven free cash flow.

Trauma and deformity products rose 26% to USD 52.6 million, while scoliosis fell 9% to USD 16.9 million because of the timing of capital placements and fewer international set sales. The consensus loss is narrower than the USD 0.30 reported, so it assumes operating leverage, with operating expenses up only 3% against gross profit up 19%. Cash, short-term investments and restricted cash fell to USD 47.9 million, which makes free cash flow important. International revenue grew 22% to USD 15.7 million, a second source of growth beside the trauma and deformity lines.

The bull case is revenue growth near 15% and a scoliosis rebound, which would support the chief executive's inflection claim and could lift the shares if guidance rises again. The bear case is a second quarter of scoliosis decline or cash falling further, which would raise financing concerns.

Pulmonx (NASDAQ:LUNG): procedure volumes and the outlook

Pulmonx (NASDAQ:LUNG) is a commercial-stage medical technology company that sells the Zephyr Endobronchial Valve, a small implant placed by bronchoscope to reduce trapped air in the lungs of patients with severe emphysema. It reports after the close on Tuesday, October 27, 2026, with consensus calling for a loss of USD 0.26 per share in market data. In the second quarter, announced on Wednesday, July 29, 2026, revenue was USD 22.8 million and the net loss narrowed. A published call summary describes the quarter as ahead of consensus, and the shares rose about 14.4%.

Revenue follows the number of treated patients, which depends on referrals from pulmonologists, hospital procedure suite capacity and payer coverage. Because the business is loss-making, investors weigh revenue growth, especially in the United States, against the pace of cash burn, and gross margin serves as a proxy for scale. The full-year revenue and gross margin outlook set in July is the benchmark for this report. Sector read-across comes from larger respiratory and surgical device companies reporting in the same season.

The bull case is revenue at or above USD 22.8 million, a further narrowing of the loss and a reiterated outlook. The bear case is a slower procedure ramp, lower gross margin or a cut to the outlook, which small-capitalisation device shares have often punished sharply.

Where Things Stand

The answer is that the three can balance growth against losses only if growth is visible in the figures that guidance frames. Beta Bionics (NASDAQ:BBNX) needs sales within USD 131 million to USD 136 million and a pharmacy mix near 39% to offset operating costs rising about 37%. OrthoPediatrics (NASDAQ:KIDS) needs scoliosis to recover and cash of USD 47.9 million to hold, while Pulmonx (NASDAQ:LUNG) needs a reiterated outlook to keep its July gain. Guidance is likely to move the shares more than the loss per share.

The next catalysts are the three releases after the close on Tuesday, October 27, 2026 and the Federal Reserve decision on Wednesday, October 28, 2026. Consensus figures and guidance are estimates, not guarantees, and this is not investment advice.